Subdermal Contraceptive Implants Market Size

Subdermal Contraceptive Implants Market size was over USD 1.08 billion in 2024 and is likely to reach USD 1.73 billion by the end of 2037, witnessing around 3.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of subdermal contraceptive implants is assessed at USD 1.11 billion.

The reason behind the growth is impelled by the rising count of unintended pregnancies. Subdermal contraceptive implants is an effective method to avoid unwanted pregnancies for women and couples, as it can stop pregnancies for three to five years. For instance, globally, there are more than 120 million unplanned pregnancies per year, or close to half of all pregnancies.

The rising governmental initiative to utilize contraceptive procedures are believed to fuel the market growth. For instance, the World Health Organization (WHO) is supporting nations to better their contraceptive policies and practices and also taking part in the development of new contraceptive methods.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of subdermal contraceptive implants is assessed at USD 1.11 billion.

The subdermal contraceptive implants market size was over USD 1.08 billion in 2024 and is likely to reach USD 1.73 billion by the end of 2037, witnessing around 3.7% CAGR during the forecast period i.e., between 2025-2037. Rising count of unintended pregnancies and the rising governmental initiative to utilize contraceptive procedures will drive the market growth.

North America industry is estimated to hold largest revenue share 55% by 2037, impelled by availability of contraceptive implants in the region.

The major players in the market are Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, Gerresheimer AG, Pfizer, Inc., Novartis AG, Schott AG, Eli Lilly and Company, and others.

Subdermal Contraceptive Implants Market Size